Back to discover
Disease

Narcolepsy-cataplexy syndrome

Also known as Gelineau disease, Gelineau syndrome, Gelineau's syndrome, Gélineau disease+3 more

Gelineau disease, Gelineau syndrome, Gelineau's syndrome, Gélineau disease, narcolepsy type 1, narcolepsy with cataplexy, narcoleptic syndrome.

12
Associated genes
2
Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 industry developments reported.
Industry & Market3View
Activity timeline3

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Solriamfetol hydrochlorideapproved

Original application approval — Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adu… (2020)

Pitolisantapproved

Original application approval — Wakix is indicated in adults, adolescents and children from the age of 6 years for the tr… (2016)

Sodium oxybateapproved

Original application approval — Treatment of narcolepsy with cataplexy in adult patients. (2005)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

Product approvals and authorisations
2020emaOriginal application approval — Solriamfetol hydrochloride· Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). source ↗
2016emaOriginal application approval — Pitolisant· Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1). source ↗
2005emaOriginal application approval — Sodium oxybate· Treatment of narcolepsy with cataplexy in adult patients. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

MOG0.51HCRT0.50HRH30.46EIF3G0.45PPAN0.45CTSH0.44CD2070.35P2RY110.20ANGPTL60.16SIRPG0.15NEMP20.07PRSS580.05

Disease biology

2 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Myelin-oligodendrocyte glycoproteinvia MOG0.51Histamine H3 receptorvia HRH30.46

Reference

Authoritative identity, definition & identifiers.

Synonyms

Gelineau disease, Gelineau syndrome, Gelineau's syndrome, Gélineau disease, narcolepsy type 1, narcolepsy with cataplexy, narcoleptic syndrome

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.